Search

everythinglearnresearchcommunity

for

Search:↓

A man with a rare skin condition and a new gene mutation developed high calcium levels due to his treatment.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

SIG-1451 could be a promising new treatment for atopic dermatitis.

ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.

The artificial skin promotes better wound healing and skin regeneration.

Nanotechnology shows promise for better drug delivery and cancer treatment.

Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.

Infrared light can trigger drug release from gold nanoparticle carriers in hair follicles.

The gel with apocynin-loaded nanoparticles shows promise for treating rheumatoid arthritis.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Existing drugs, including a blood pressure medication, show promise as new treatments for influenza.

New therapy helps treat hair loss.

PEVIII is a promising treatment for Pseudomonas aeruginosa keratitis.

The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.

Advanced therapy medicinal products show promise for vitiligo treatment with fewer side effects, but affordability is a challenge.

Nanoemulgel improves delivery and effectiveness of plant-based drugs for various conditions.

A new method quickly detects hair changes from EGFR inhibitors using a microscope.

Repurposing existing drugs and using micronutrients may effectively target cancer stem cells and improve cancer treatment.

Nanoparticle delivery can reduce side effects of the cancer drug doxorubicin.

Misdiagnosis led to unnecessary treatment due to a genetic mutation affecting thyroid hormone resistance.

Integrative hair therapy improved hair loss and regrowth.

The UK Court of Appeal ruled that new dosing regimens for drugs can be patented, aligning with the European Patent Office's approach.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Personalized skin rejuvenation using genomics shows promise but needs more research.

The method reliably profiles eicosanoids and shows epitestosterone reduces their levels, similar to common anti-inflammatory drugs.

EDA2R is a key gene linked to ageing and diseases, and targeting it may help treat conditions like hair loss and chronic diseases.